Avidity Biosciences
Approach: Antibody Oligonucleotide Conjugate
Status: Preclinical
Description of DM1 program on company website
June 17, 2019 Patent Application
September 14, 2019 Presentation at Myotonic conference (starts at 15:20)
November 13, 2019 Article on Avidity's $100 million capital raise
May 22, 2020 S-1 for IPO. States it plans to start a clinical trial of its myotonic dystrophy T1 drug, AOC 10001, by the end of 2021
Sept. 2020 Presentation at Myotonic Dystrophy Foundation annual conference (starts at 1:19)